A Democratic bill with 2 Republican cosponsors · See all 3 cosponsors
Last activity — Read twice and referred to the Committee on Finance.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "PBM Reporting Transparency Act," requires the Medicare Payment Advisory Commission (MedPAC) to submit two specific reports to Congress. These reports focus on agreements with pharmacy benefit managers regarding prescription drug plans and MA-PD plans. The first report must include descriptions of trends, patterns, and an analysis of how agreements affect enrollee out-of-pocket spending and pharmacy reimbursement. The second report must describe changes over time. Both reports allow for recommendations from the Commission.
Yes· 3 of 7
- Scored +5
Does this make what the government does easier for the public to see?
The bill increases transparency by requiring MedPAC to report on the trends and impacts of agreements made by pharmacy benefit managers.
- Scored +3
Would people over 65 be better off under this?
The bill benefits seniors by analyzing how drug plan agreements affect their out-of-pocket costs under Medicare.
- Scored +3
Would retired people be better off under this?
The bill provides oversight into Medicare drug plan costs which directly impacts the financial well-being of retirees.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency on Spending: The initial report requires an analysis of how agreements affect plan enrollee out-of-pocket spending (Section 2, Paragraph 1, Subparagraph B). This could help people understand how these agreements impact their personal costs.
-
Insight into Pharmacy Reimbursement: The bill requires a description of the effects of agreements on average pharmacy reimbursement (Section 2, Paragraph 1, Subparagraph B). This provides a look at how these agreements impact the pharmacy industry.
-
Identification of Trends: The report requires a description of trends and patterns, including averages and totals (Section 2, Paragraph 1, Subparagraph A). This provides a clear picture of how these agreements are evolving.
-
Expert Recommendations: The Commission is empowered to provide any recommendations it determines are appropriate (Section 2, Paragraph 1, Subparagraph C and Paragraph 2). This allows for expert suggestions to be presented to Congress.
Potential Negative Impacts for People
- No specific negative impacts are mentioned in the text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would retired people be better off under this? — The bill provides oversight into Medicare drug plan costs which directly impacts the financial well-being of retirees. Would people over 65 be better off under this? — The bill benefits seniors by analyzing how drug plan agreements affect their out-of-pocket costs under Medicare. Would households on low incomes be better off under this? — Increased transparency regarding out-of-pocket spending can help protect low-income enrollees within the Medicare system. Would veterans be better off under this, taking everything together? — Veterans utilizing Medicare-related drug plans may benefit from increased oversight of PBM spending and costs.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill increases transparency by requiring MedPAC to report on the trends and impacts of agreements made by pharmacy benefit managers.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by requiring analysis of how PBM agreements affect enrollee out-of-pocket spending.
- Healthcare
- Does this lower the price of prescription medicines? — By analyzing out-of-pocket spending and pharmacy reimbursement trends, the bill provides a mechanism to potentially identify and address rising drug costs.
- 1/29/2026
- Read twice and referred to the Committee on Finance.
- 3 Cosponsors added.
- Introduced in Senate
Catherine Cortez MastoDemocrat · Nevada
Roger MarshallRepublican · Kansas
Thomas TillisRepublican · North Carolina